Man Group’s KalVista Pharmaceuticals KALV Stock Holding History

Man Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,576	Closed	-$857K	–	2476
2026 Q1	$857K	Buy	42,576 +25,130	+144%	+$405K	﹤0.01%	1891
2025 Q4	$282K	Buy	+17,446	New	+$231K	﹤0.01%	2039
2019 Q3	–	Sell	-9,381	Closed	-$208K	–	1849
2019 Q2	$208K	Hold	9,381	–	–	﹤0.01%	1802
2019 Q1	$268K	Buy	+9,381	New	+$203K	﹤0.01%	1831

Other funds holding KALV

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Man Group's KALV Position: Q2 2026 in Review

Man Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 42,576 shares — an estimated $857K sold.

Man Group first reported a position in KALV in Q1 2019 and held it in 4 quarters. The position peaked at $857K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Man Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Man Group sold 42,576 KalVista Pharmaceuticals shares in Q2 2026, an estimated $857K.
Man Group first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Man Group's KalVista Pharmaceuticals position peaked at $857K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.